• Small Molecules
      • Discovery
    • Large Molecules
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Webinars

Choose from a variety of resources to get a better understanding of Syngene’s point of view, expertise or approach to drug discovery, development and manufacturing to ensure client success.

Play Video

Drug Repurposing: Perspective on an emerging pharmaceutical solution

Learn from our client PharmAust, how drug repurposing is an effective alternative approach to traditional drug discovery, the changing landscape of drug repurposing, steps in the drug repurposing journey when moving up to GMP scale and more.

Play Video

Creating the RIGHT toxicology strategy: Learning from the past to shape the future

Learn from our client ApconiX,  the key trends in the toxicology space,  how AI and in vitro studies co-exist and support an overarching tox strategy and more.

Play Video

Interpreting Clinical Relevance of Immunogenicity Data Syngene

Learn from our client, Merck & Co., the relevance of PK and ADA data in a clinical setting, impact of neutralizing antibodies on PK and more.

Play Video

Targeted Protein Degradation

Listen to what  our client, C4 Therapeutics has to say, about  the exciting opportunity that Targeted Protein Degradation represents to Biopharma companies around the world.

Play Video

Advancing molecules from discovery to the clinic: A blueprint

Our client, Albireo, recently cleared phase-3 clinical trials for its drug Odevixibat. Learn from  Albireo’s experience, how to advance molecules from discovery to the clinic in the shortest possible time.

Play Video

Building a successful ICH Stability CoE: Collaboratingn at scale

Syngene-Baxter R& D Centre is going strong even after 10 years. Undertand from our experts, the key elements of a great research partnership in ICH Stability Studies.

This Website uses Cookies

We use cookies to improve your experience on our site and show you information relevant to your requirements.

To find out more, read our Privacy Policy and Cookies Policy.

To download, Please share your details

To download, Please share your details